Arcus Biosciences, Inc.
RCUSHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeArcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. At a $3.44B market cap, Arcus Biosciences, Inc. ranks as a mid-cap company within healthcare. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody.
Market Cap
$3.44B
Beta
0.80
P/E (TTM)
—
P/E (Fwd)
-8.82
EPS (TTM)
$-3.26
EPS (Fwd)
$-3.10
ROE
-70.0%
ROA
-23.1%
Cash
$822.0M
Total Debt
$232.0M
Free CF
-$156.0M
52W Change
199.1%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $822.0M in cash comfortably exceeding the $232.0M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$156.0M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -70.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $112.0M (2022) to $247.0M (2025), reflecting a 121% increase over the period.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing RCUS.